iNtRODUCtiON
Lymphoepithelioma-like carcinoma (LELC) of the lung is a rare entity worldwide, with limited case series or case reports having been published. It was first reported by Bégin et al in 1987, 1 and categorised as a form of large cell carcinoma according to World Health Organization classification. 2 It is more prevalent in Asia, 2 notably in Southeast Asia. In the past two decades, studies reported its histological resemblance to undifferentiated nasopharyngeal carcinoma (NPC), 2, 3 which is associated with Epstein-Barr virus (EBV) and occurs almost exclusively in Asians 2,4-6 and exhibits specific radiological features. 7, 8 Limited case series comparing treatment outcomes of patients with LELC and non-LELC non-small-cell lung cancer (NSCLC), 2, [9] [10] [11] [12] reported that the former had superior chemo-and radio-sensitivity 2,9-11 and was associated with statistically significant better survival of patients with stages II to IV disease. 12 The objective of this study was to evaluate the treatment outcomes in a series of 22 patients with primary pulmonary LELC treated at our institution, and compare them to other reported series. Systemic treatment strategies effective against NPC that could have a role in this rare disease entity were also explored.
MEtHODS
The medical records (both paper and electronic) of 22 patients with pathologically confirmed primary pulmonary LELC treated in the Pamela Youde Nethersole Eastern Hospital from 1994 to 2012 were reviewed. Primary pulmonary LELC was defined pathologically as having a characteristic morphology. It entailed presence of undifferentiated carcinoma cells with ill-defined cytoplasmic borders arranged in syncytial sheets and nests separated by broad areas of lymphocytic reaction, and tumour cells growing in a diffuse manner and mimicking malignant lymphoma. 2, 6 The diagnosis was confirmed by in-situ hybridisation for EBV-encoded small nuclear RNA (EBER) status. 4 Clinical (with computed tomography [CT]) or pathological restaging was performed according to the International Union Against Cancer (UICC) / American Joint Committee on Cancer (AJCC) 6th edition. For operable disease, final pathology reports were studied and restaging performed. For patients with surgically or medically inoperable disease, their initial CT films and reports were reviewed and restaged. To exclude metastasis from primary NPC, initial presenting symptoms were documented. All patients had no upper aerodigestive symptoms including nasal congestion, hearing loss, neck mass etc. Of 22 patients, 15 had nasopharyngoscopy to rule out NPC. Two others had positron emission tomography ruling out nasopharyngeal involvement. Patient characteristics, including age, gender, and smoking status, were evaluated. Treatment modalities including surgery, chemotherapy schemes and radiation techniques, doses and fractionation were explored. Patients who completed radical treatment were followed up every 3 to 4 months in the first 2 years, then every 4 to 6 months in the 3rd to 5th year and yearly after 5 years according to department policy, with physical examination and chest radiograph done at every visit and contrast CT 3 to 12 months post-treatment that was repeated about 1 year after the first post-treatment image. This imaging was to confirm disease in remission. Patients treated with palliative intent were followed up according to clinical needs. For those given a primary radical dose of radiotherapy (i.e. biologically equivalent total dose applied in 2 Gy fractions [EQD2] = 60 Gy or above), their chest radiographs and contrast CT images were re-
方法：回顧性分析所有1994至2012年期間經病理學證實的原發性肺LELC的患者紀錄。分析治療方式

和結果，包括局部控制率、無病生存率和總體生存率。
結果：發現原發性肺LELC22例。病例的隨訪期中位數為33個月（範圍：1日至106個月）。對於第I
至第II期的患者來說，手術是主要的治療方法。於中位隨訪期68個月後，接受高劑量放療（EQD2為
60 Gy）的晚期無轉移瘤患者（n = 5）局部控制率達100%；伴或不伴以鉑類藥物為基礎的化療均如 此。五年無進展生存率（PFS）和總體生存率（OS）分別為53%和80%。至本文發表時，尚未獲得 PFS和OS的中位數數據。至於無法施以根治性放療第III及第IV期患者，有12例因接受含鉑類雙藥聯 合方案的姑息性化療而無瘤中位生存期達至10個月。第I-II、III和IV期的五年OS分別為41%、38%和 25%（p = 0.61），其中位生存期分別為58、30和19個月。 結論：本系列研究結論呼應之前的報道，即原發性肺LELC的治療效果是樂觀的。 evaluated according to Green et al's criteria 13 to exclude local disease. These entailed complete disappearance of all evidence of malignant disease, or residual radiographic abnormalities assessed by CT 3 and 6 months after completion of radiotherapy, which then remained stable for an additional 6 months or more. Treatment response to palliative chemotherapy was reevaluated according to RECIST criteria version 1. Overall survival (OS) was measured from the date of diagnosis to death. Progression-free survival (PFS) was calculated from the start of treatment to disease progression or death. We censored at the follow-up date if there was no radiological / clinical progression or death. PFS and OS were calculated by the Kaplan Meier method.
RESUltS
Among the 22 patients, the numbers with stage I, II, III, and IV (AJCC 6th edition) were 2, 4, 8, and 8, respectively. The male-to-female ratio was 6:16. The mean age at diagnosis was 59 (range, 39-78) years. The majority (n=20, 90%) were EBER stain-positive after the year 1995 (after journals published the association of EBV with pulmonary LELC). In all, 59% were never-smokers, whereas 22% were smokers and in 18% the status was unknown. The median follow-up duration was 33 months (range, 1 day to 106 months). Treatment summaries of each patient are shown in Table 1 .
For early staged patients (stages I-II, patient Nos. 1-6), five were treated surgically. Only one received palliative radiotherapy due to suboptimal clinical status. Three out of the five patients relapsed; one had a local and regional relapse after 18 months (patient No. 3) and two had distant relapses both after 29 months (patient Nos. 2 and 4). The one with local-regional relapse was successfully salvaged with definitive chemoradiotherapy and remained disease-free after 67.9 months of followup.
Of the 22 patients, 12 had unresectable non-metastatic disease at primary presentation (n = 11) or relapse (n = 1), based on UICC 6th edition IIB-IIIB staging. Six patients were treated radically with a combination of surgery, radiotherapy, and chemotherapy; the other six had a poor clinical status or their disease was deemed beyond radical radiotherapy, and thus they were treated palliatively. Five out of the six patients (patient Nos. 3-5, 9, and 10) were treated with a primary radical radiotherapy dose of EQD2 60 Gy that covered the gross disease including the tumour and lymph nodes. Four out of five patients were given 3D conformal radiotherapy, while only one received 2D radiotherapy (in the 1990s). Four out of five patients received either sequential or concurrent platinum doublets chemotherapy. Their median follow-up duration was 68 months (range, 33-106) months. All five patients (100%) achieved control of local disease on serial imaging until the last followup. Three patients remained disease-free on last followup while two relapsed with distant lesions after 29 and 18 months. The median PFS and OS had not been reached at publication of this series. The 5-year PFS and 5-year OS were 53% and 80%, respectively (Figures 1  and 2 ).
Twelve patients with stage III-IV disease at presentation or relapse who were not amenable for radical radiotherapy or surgery (patient Nos. 2, 7, 11-13, 15-21) were given first-line palliative chemotherapy with platinum doublets, which included cisplatin or carboplatin combined with gemcitabine (n=6), 5-fluorouracil (n=4), etoposide (n=1), mitomycin plus ifosphamide (n=1) from 1 to 6 cycles. The median time to progression was 10 (range, 1-23) months. Secondline treatment included retrying platinum doublets (n=3), capecitabine (n=7), pemetrexed (n=1), and erlotinib (n=3). The time to progression of patients treated with platinum doublets, pemetrexed, and erlotinib were 5-14 months, 5 months, and 0.5-1.8 months, respectively. For the seven patients treated with capecitabine, three patients survived 0.3-17 months; the other four were still having active treatment at the time of data collection. 
DiSCUSSiON
The favourable local control rate and survival outcomes exhibited in the current study echoed with those of previous series as shown in Table 2 . [9] [10] [11] [12] 15, 16 However, prospective randomised trials are warranted to validate this hypothesis because of the intrinsic limitations of retrospective analysis and limited patient numbers.
Treatment strategies implemented in previous series were largely similar to those used for NSCLC. Reviewing available series on PubMed and the Cochrane review (Table 2) found that primary pulmonary LELC was usually treated using a multimodality approach. Stage I-II diseases were mainly treated with surgery with or without adjuvant chemotherapy. Meanwhile, there are inadequate data to infer whether early stages pulmonary LELC can be treated with radiotherapy alone. A recent series published by Liang et al 15 did not show survival benefit for adjuvant chemotherapy in stage II patients with complete resection, but the number of patients was small. Further studies are again warranted for confirmation.
Advanced non-metastatic diseases were treated with combined modality treatment including various platinum doublet chemotherapy regimens and radiotherapy. Chemotherapy included platinum combined with 5-fluorouracil 9,10 gemcitabine, taxane, etoposide, ifosphamide and vinorelbine, 15, 16 in which various doses of radical radiotherapy from 40-70 Gy, 2-2.5 Gy per fraction were used. The 2-year OS in several series was around 60 to 80% (Table 2 ). In our series, the local control rate and OS of patients with advanced nonmetastatic disease treated with radiotherapy of EQD2 60 Gy combined with platinum doublets was excellent. However, it is worth highlighting that the radiotherapy techniques used in various pulmonary LELC series were heterogeneous, owing to the scanty number of cases encountered over more than 10 years. There have been further advancements in radiotherapy techniques, including intensity-modulated radiotherapy, rapid-arc or hybrid rapid-arc techniques, 17 and the use of different respiration motion techniques including respiratory gating and 4D CT. 18 Currently, we are therefore able to deliver radiotherapy to lung tumour with a more stringent margin, a more favourable dose coverage, and tolerable mean lung dose. Thus, more favourable outcomes for this specific disease entity are anticipated Table 2 . Summary of treatment details and outcomes of pulmonary LELC in major series available on PubMed search (n ≥ 5). [9] [10] [11] [12] 15, 16 Abbreviations: CRT = chemoradiotherapy; FU = follow-up; OS = overall survival; PR = partial remission; RR = response rate; RT = radiotherapy; SD = static disease. in the coming years. On the other hand, the 5-year survival stage III ordinary NSCLC remains less than 20%, 19 despite better radiotherapy planning techniques in recent years.
For advanced disease beyond radical radiotherapy portal or metastatic diseases, different treatment options were attempted in previous series. [9] [10] [11] [12] 15, 16 First-line platinum chemotherapy apparently gave a more favourable PFS compared with ordinary NSCLC. In our current study, the time to progression for first-line platinum double was 10 months, as compared with 5 months for firstline pemetrexed / cisplatin in stage IIIB / IVA nonsquamous lung cancers. 20 Second-line treatment options remain controversial. Physicians attempted the secondline chemotherapy agents as used in NPC owing to the histological resemblance of NPC and pulmonary LELC. The beneficial use of capecitabine, which is also used in NPC, 21, 22 was reported by Ho et al 23 and was echoed by our series. Apart from capecitabine, retrying platinum doublets may be another treatment option if the patient's tumour is platinum-sensitive at initial presentation, as shown by the satisfactory time to progression (5-14 months) in our series. Further studies are awaited to confirm the effectiveness of different systemic agents.
The role of serum EBV-DNA has been investigated in previous series. In terms of disease monitoring, good correlation of disease status with serum EBV-DNA level in pulmonary LELC was reported in two previous studies published by Ngan et al 24, 25 For predictive or prognostic factors, in those who underwent complete resection, Liang et al 15 found that early tumour stage, a normal serum lactate dehydrogenase level, a normal serum albumin level, and absence of lymph node metastasis had significantly better OS (p < 0.05). The serum albumin level was also an independent prognostic factor (p = 0.005) in this series. However, it is difficult to draft a prognostic score for decisions on treatment strategy based on the available literature. It may be meaningful for future studies to explore the use of serum EBV-DNA to predict relapses and prognosis as for in NPC. 26, 27 This approach may give more clues on the use of adjuvant chemotherapy in early stage disease.
To improve future treatment outcomes, it will be necessary to recruit patients into randomised control trials with standardised treatments, follow-up intervals and other management modalities.
CONClUSiON
Our series of patients with primary pulmonary LELC achieved favourable outcomes, echoing previous findings. Patients having early stage disease should be treated surgically. Radical chemoradiotherapy with EQD2 60 Gy and platinum doublets gives excellent survival outcomes in those with unresectable nonmetastatic disease. Chemotherapy agents used in advanced or metastatic NPC, including platinum doublets or single agent capecitabine, can be attempted in pulmonary LELC patients. Serum EBV-DNA may be useful in disease monitoring. Further randomised studies are warranted.
